Umoja Biopharma, Inc.is an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies.IASO Bio and Umoja Biopharma entered into a research collaboration to bring off-the-Shelf therapies to patients with hematological malignancies.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases.IASO Bio and Cabaletta Bio entered into an exclusive worldwide license agreement for clinically validated CD19 binder.
Innovent Biologics has a strong track record in research and development of high-end biomedicines, clinical studies and product launch. IASO partnered with Innovent in the joint development of a BCMA-targeted CAR-T cell therapy.
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines.IASO Bio,Innovent and Sana have entered into an agreement pursuant for clinical validated BCMA CAR construct.
The University of Pennsylvania is a renowned private research university and a member of the Ivy League. IASO collaborated with UPenn in the development of optimal processes for cell therapies.
Adimab is a global leader in discovery and optimization of fully-human monoclonal and bispecific antibodies. IASO partnered with Adimab in the development of several antibody series.
Tongji Hospital (TJH) is one of the leading hospitals specializing in cell therapies. IASO and TJH have jointly conducted IIT and registrational clinical studies on multiple cell therapies.
Multiple clinical studies are underway with over 10 top-tier national hospitals with broad patient access in the areas of oncology and autoimmune diseases, including hospitals affiliated with Zhejiang University School of Medicine, Tianjin Blood Institute, and the Henan Cancer Hospital